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Blue pigment synthase A (BpsA) is a single module non-ribosomal peptide synthetase (NRPS) originally isolated 
from the bacterium Streptomyces lavendulae. It synthesises an easily detectible blue pigment called indigoidine 
from two molecules of L-glutamine in an ATP powered reaction. BpsA is readily purified and amenable to in vitro 
assays that have a variety of useful applications. By spectrophotometrically quantifying indigoidine levels it is 
possible to accurately measure the amount of L-glutamine in complex biological fluids including urine, blood 
plasma and cell culture media. This method has several advantages over existing methods for glutamine 
measurement, including that it directly reports on glutamine levels. Existing commercially available enzymatic 
kits first convert glutamine into glutamate and then measure the level of glutamate, which requires additional 
sample processing and introduces complexity if glutamate may also be present in the target sample. 
Additionally, we have shown that BpsA can also be used to measure ATP concentrations in a similar manner. 
We have further developed a BpsA based assay to detect inhibitors of 4’-phosphopantetheinyl transferases 
(PPTases). PPTases are enzymes that attach a phosphopantetheine arm to fatty acid synthases, NRPSs and 
polyketide synthases, thereby switching them from an inactive apo form to an active holo form. PPTases have 
been validated as promising drug targets in several pathogenic bacteria including P. aeruginosa and M. 
tuberculosis. In order to detect PPTase inhibition, we have shown that BpsA can be purified in its inactive apo 
form and mixed with the target PPTase as well as a candidate inhibitor in vitro. The level of PPTase inhibition 
can then be calculated by measuring the rate of indigoidine production. The assay has been optimised for high 
throughput screening and used to identify several compounds from chemical libraries that inhibit essential 
PPTases of P. aeruginosa and M. tuberculosis.  
 
 
